Evidence map›Paper›PMID 40044154›Full record

ArticleEnvironmental health and preventive medicine2025

Effects of speech duration and voice volume on the respiratory aerosol particle concentration.

Tomoki Takano, Yiming Xiang, Masayuki Ogata, Yoshihide Yamamoto, Satoshi Hori, Shin-Ichi Tanabe

Abstract read
In one paragraph

Article in Environmental health and preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tomoki TakanoDepartment of Architecture, Waseda University.
Yiming XiangDepartment of Architecture, Waseda University.
Masayuki OgataDepartment of Architecture, Tokyo Metropolitan University.
Yoshihide YamamotoArchitecture Course, Tokyo Polytechnic University.
Satoshi HoriDepartment of Infection Control Science, Juntendo University, Graduate School of Medicine.
Shin-Ichi TanabeDepartment of Architecture, Waseda University.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 (COVID-19) is transmitted via infectious respiratory particles. Infectious respiratory particles are released when an infected person breathes, coughs, or speaks. Several studies have measured respiratory particle concentrations through focusing on activities such as breathing, coughing, and short speech. However, few studies have investigated the effect of speech duration.

methodsThis study aimed to clarify the effects of speech duration and volume on the respiratory particle concentration. Study participants were requested to speak at three voice volumes across five speech durations, generating 15 speech patterns. Participants spoke inside a clean booth where particle concentrations and voice volumes were measured and analyzed during speech.

resultsOur findings suggest that as speech duration increased, the aerosol number concentration also increased. Through focusing on individual differences, we considered there might be super-emitters who emit more aerosol particles than the average human. Two participants were identified as statistical outliers (aerosol number concentration, n = 1; mass concentration, n = 1).

conclusionsConsidering speech duration may improve our understanding of respiratory particle concentration dynamics. Two participants were identified as potential super-emitters.

Indexed as

Respiratory Aerosols and DropletsSpeechVoiceAdultAerosolsCOVID-19FemaleHumansMaleSARS-CoV-2Time FactorsYoung AdultAerosolsAerosol transmissionCOVID-19Speech durationSuper-emitterVoice volume

Identifiers

PMID40044154
PMCPMC11925707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.